



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States-Batent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/026,949	12/27/2001	Yusuf K. Hamied	33396-177202 7990 EXAMINER	
26694 7:	590 11/20/2003			
VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP			COLEMAN, BRENDA LIBBY	
P.O. BOX 34385 WASHINGTON, DC 20043-9998			ART UNIT	PAPER NUMBER
	,		1624	6
			DATE MAILED: 11/20/2003	
			1	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/026,949	HAMIED ET AL.				
Office Action Summary	Examiner	Art Unit				
	Brenda L. Coleman	1624				
The MAILING DATE of this communication app						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Responsive to communication(s) filed on						
	- action is non-final					
,		secution as to the merits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-19 is/are pending in the application.						
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.	Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-19</u> is/are rejected.	☑ Claim(s) <u>1-19</u> is/are rejected.					
7) Claim(s) is/are objected to.	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correcti	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. §§ 119 and 120						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 09/540,749. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. a) The translation of the foreign language provisional application has been received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. 						
Attachment(s)		·				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 43	5) Notice of Informal Page 1	(PTO-413) Paper No(s) atent Application (PTO-152)				
		<u> </u>				

Art Unit: 1624

DETAILED ACTION

Claims 1-19 are pending in the application.

Information Disclosure Statement

1. The information disclosure statement filed October 8, 2003 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each U.S. and foreign patent; each publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered. The non-patent literature labeled C1 is not present in the application. It is requested that the applicants provide a copy of this reference in order to complete the record.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 1-19 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The psychotic condition and gastrointestinal conditions of claims 43 and 44 are not described in the specification. While the specification provides for the use of olanzapine in the treatment of schizophrenia, schizophreniform disorders, psychosis, mild anxiety states and

Application/Control Number: 10/026,949

Art Unit: 1624

1//OOM(OF NAME) - 10/020,0-

functional bowel disorders, there is no description for the broad genus psychotic condition and gastrointestinal conditions.

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The specification does not have working examples on the use of Forms III, IV or V olanzapine. The absence of working examples is one of the factors to be considered in deciding whether the practice of an invention would involve undue experimentation. There must be evidence to justify the contention that the claimed compounds can be useful in the treatment of "psychotic condition and gastrointestinal conditions". It is difficult to treat many of the disorders claimed herein. Recent studies on experimental and clinical pharmacology of nicotinic acetylcholine receptors cited in Annual Reports in Medicinal Chemistry indicate that the following disorders may be associated with nicotinic acetylcholine receptors: senile dementia of the Alzheimer's type, Parkinson's disease, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, depression, attention deficit disorder, anxiety, dyslexia, schizophrenia, Tourette's syndrome and smoking cessation. The "nicotinic" effect with respect to Alzheimer's is hypothesized. Parkinson's Disease is "presently of unknown etiology" and recent studies have exhibited dosing problems as well as "unusually high placebo effects". The pathophysiology of Tourette's Syndrome is unknown. The treatment of ulcerative colitis is currently "limited to anti-inflammatories, immunosuppressants and antibiotics". Additionally, there are other pathological nonArt Unit: 1624

CNS conditions, such as pouchitis and influenza virus-induced pneuomonitis, where nicotine efficacy has been reported, but remains to be confirmed.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

- 3. Claims 1, 8-12, 15, 16 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
 - a) Claim 1 and claims dependent thereon are vague and indefinite in that it is not known what is meant by the second occurrence of FORM IV in the Table. It is believed that the applicants intended FORM V.
 - b) Claim 9 recites the limitation "x-ray powder diffraction pattern" for Form V.

 There is insufficient antecedent basis for this limitation in the claim.
 - c) Claim 11 is vague and indefinite in that it is not known what is meant by the second occurrence of FORM IV in the Table. It is believed that the applicants intended FORM V.
 - d) Claim 12 and claims dependent thereon are vague and indefinite in that it is not known what is meant by the second occurrence of FORM IV in the Table. It is believed that the applicants intended FORM V.
 - e) Claim 16 and claims dependent thereon are vague and indefinite in that it is not known what is meant by the second occurrence of FORM IV in the Table. It is believed that the applicants intended FORM V.

Page 5

Application/Control Number: 10/026,949

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 703-305-1880. The examiner can normally be reached on 8:30-5:00 Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Brenda Coleman

Primary Examiner Art Unit 1624

November 18, 2003